Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo.
Concanavalin A, endotoxin, poly I: C, and tumour necrosis serum (TNS) were compared for antitumour activity against Meth A sarcoma transplanted in syngeneic BALB/c mice and their capacity to induce tumour necrosis factor (TNF), heat-stable cytostatic factors, and heat-labile interferon in the blood of normal and Corynebacterium parvum-pretreated mice. All the agents induced hyperemia and inhibition of mitosis at 4 h, and by 24 h many tumours had a dark necrotic centre. Subsequent tumour growth was inhibited and in some of the treated mice tumours regressed completely. Poly A: U and normal mouse serum did not induce regression and their effects were less marked in all other respects, suggesting that these events may be linked. The necrotizing effects of concanavalin A and poly I: C are unlikely to be mediated by TNF, because neither agent could mimic endotoxin in eliciting RNase-resistant necrotizing and regressing activity in the serum of mice pretreated with C. parvum. Poly I: C did not induce strong cytostatic activity in the sera of C. parvum-treated mice, and for this and other reasons these factors are unlikely to be responsible for the observed effects. Concanavalin A, endotoxin, and poly I: C induced high levels of serum interferon but purified interferon had only weak antitumour activity in the Meth A system, suggesting that interferon may not be the mediator. From these and other data it is concluded that there is no clear relationship between the capacity of the agents to induce tumour necrosis and their capacity to elicit TNF, cytostatic factors, and interferon.
D000818:Animals; D000970:Antineoplastic Agents; D003208:Concanavalin A / Q000627:therapeutic use; D004731:Endotoxins / Q000627:therapeutic use; D005260:Female; D006023:Glycoproteins / Q000096:biosynthesis*; D006131:Growth Inhibitors / Q000096:biosynthesis*; D007372:Interferons / Q000096:biosynthesis*; D051379:Mice; D011070:Poly I-C / Q000627:therapeutic use; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha
D000970:Antineoplastic Agents; D004731:Endotoxins; D006023:Glycoproteins; D006131:Growth Inhibitors; D014409:Tumor Necrosis Factor-alpha; D003208:Concanavalin A; D007372:Interferons; D011070:Poly I-C